Biostage | Regenerations Ahead

Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial

FDA's approval of Biostage's first IND is an extremely important milestone for Biostage as it will transition Biostage into a clinical stage company. >>>

Biostage Reports Q1 2022 Financial Results and Corporate Highlights
Meet the New Chief Executive
Invest in Biostage and help bring our products to the patients who need them
Biostage has a “breakthrough” technology that is “revolutionary” and would “have considerable clinical use”
Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial
See how Biostage’s Esophageal Implant works to regenerate the esophagus inside the human body
the first ever regeneration of the esophagus in a human cancer patient was done with our product at Mayo clinic and published in JTO Clinical and Research Reports

Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective Treatment

Approximately 1 in 4,000 babies, in the US alone, are born with this congenital defect. Find out how Biostage is working to answer this unmet medical need. >>>

How Biostage Technology Restore Organ Function

Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold. >>>

Biostage receives FDA approval for 10 patient phase 1 and phase 2 clinical trial

Esophageal Atresia:A Life-Threatening Conditionthat Demands Effective Treatment

How Biostage Technology Restore Organ Function

Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective Treatment